Study for Patients with Paroxysmal Supraventricular Tachycardia (PSVT)

PriMED Clinical Research is hosting an option for patients who suffer from PSVT, or abnormally fast heart rate. This study is looking at a medication called Etripamil, an intranasal spray that you will be able to use without going to a hospital or physician’s office during episodes of PSVT. This medication would address an unmet need since there are currently no similar products available for self-administered treatment episodes of PSVT.

What is this Medication?

While research is still ongoing, this medication is quickly metabolized by the body, thereby avoiding long-term side effects that can occur with chronic drug therapy. Also, designed to be rapidly absorbed into the bloodstream within minutes, allowing it to act quickly. If approved, Etripamil will be a new, potent, and fast-acting calcium channel blocker in the form of a nasal spray to stop PSVT, and other episodic cardiovascular conditions, whenever and wherever they occur.

Who can participate?

  • Adult 18 years or older diagnosed with PSVT
  • Male or females who are not currently pregnant or breastfeeding.

Patient’s who have the following are not eligible for this study:

  • History of ACS or stroke within 6 months
  • Wolff-Parkinson-White Syndrome
  • Second- or third-degree AV block

What will happen in the study?

You will come into our PriMED Clinical Research office for your first screening visit to confirm you qualify and consent to the study. There will be at most 7 visits total the timeline depending on your frequency of PSVT episodes. Each visit you will be compensated $100 for your time and travel. All study-related care and evaluations will be at no cost to you or your insurance. Your health will be evaluated at each appointment by our research nurse and physician.

Where will these visits be located?

At our PriMED Clinical Research office

948 Patterson Rd Dayton, OH 45419

How can I learn more information or sign up?

Call our team at 937-534-4238 or fill out an interest form

https://www.milestonepharma.com/research-development/etripamil/